Her2 immunohistochemical evaluation by traditional microscopy and by digital analysis, and the consequences for FISH testing  by Marcuzzo, Thomas et al.
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Aim:  Her2  protein  is  the key  marker  determining  the  choice  of Herceptin  therapy  after  a  diagnosis  of
breast  cancer.  Its evaluation  is made  in most  laboratories  by immunohistochemistry,  and  interpreted  by
a pathologist  using  an  optical  microscope,  a process  subject  to inter-observer  variability,  particularly  for
samples  scored  as  equivocal  (2+).  Software  analysis  products  have  been  introduced,  seeking  to reduce  this
variability.  In this  study,  we  compared  the  results  of both  traditional  evaluation  and  a  speciﬁc  software
package  (VISIA  Imaging)  to those  from  ﬂuorescent  in situ hybridization  (FISH).
Materials and methods:  We  selected  176  cases  of  invasive  breast  cancer  sampled  during  2012–2014  that
were  classiﬁed  as equivocal  after evaluation  of  Her2  immunohistochemistry,  and  that  were  also  evaluated
by  FISH.  Each  tissue  slide  was  scanned  with  a digital  D-Sight  Fluo  2.0  microscope  and  analysed  with  VISIA
Imaging  S.r.l.  software.  The  ﬁnal  results  were  categorised  as  follows:  negative  (0–1+),  equivocal  (2+),  or
positive (3+). Then  each  result  was  compared  to that obtained  by FISH.
Result:  The  digital  method  conﬁrmed  85  samples  (48.3%)  as  equivocal  (2+), while  23 (15.1%)  were  reclas-
siﬁed  as negative  (1+)  and  44 (28.9%)  as positive  (3+).  Of the  176  cases,  24  (13.6%) were  not  suitable
for digital  analysis  (inadequate).  Of 67  reclassiﬁed  cases  (1+  or 3+),  62  were  in  agreement  with  FISH
results  (concordance  rate 92.5%).  The sensitivity  and  speciﬁcity  of  the  digital  method  were  100%  and  82%,
respectively.
Conclusion:  The  application  of  this  analysis  software  led  to  an  improvement  in  the  interpretation  of  cases
classiﬁed  as  equivocal,  decreasing  the need  for  FISH  and  increasing  diagnostic  certainty.
©  2016  The  Authors.  Published  by Elsevier  GmbH.  This  is an  open  access  article  under  the  CC  BY. Introduction
The expression of the human epidermal growth factor 2 (Her2)
embrane protein is a key marker in the prognostic and predictive
ssessment of breast cancer [1]. Its evaluation is generally made
sing immunohistochemical tests interpreted by a pathologist, and
sing in situ hybridisation testing for uncertain cases [2]. How-
ver, a pathologist’s evaluation of optical microscopy is a subjective
arameter, open to inter-observer variability [3]. Many efforts have
een made to ﬁnd a more objective procedure, including digital
nalysis [4–8]. In this study, a digital analysis software product for
er2 immunohistochemical evaluation was tested. The software
ses slide images previously acquired with a digital microscope and
∗ Corresponding author.
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semiautomatic analysis of the virtual slide, classifying the sample
as positive (3+), negative (0–1+), or equivocal (2+). We  evaluated
whether the application of this software analysis could lead to an
improvement in the interpretation of equivocal cases, decreasing
the use of FISH. We  examined the concordance rate between the
results obtained by digital analysis and by FISH.
2. Materials and methods
We selected 176 cases of invasive breast cancer diagnosed
during 2012–2014, classiﬁed as equivocal after Her2 immunohisto-
chemical slide evaluation. A conﬁrming FISH test was made only on
equivocal cases [1]. All slides were selected from the archive of the
Institute of Pathological Anatomy and Histology of the Academic-
Hospital public-service corporation “Ospedali Riuniti” of Trieste,
Italy. Immunohistochemistry was  performed after previous tissue
ﬁxation (10% neutral buffered formalin) and parafﬁn embedding.
le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Immunohistochemical procedure.
√
Antigen retrieval: application of a heat procedure with PT-Link
instrument (Bioptica) and W-CAP EDTA Buffer pH 8.0 (Bioptica):
©  Preheat: heating of the buffer, its temperature increases from room
temperature to 65 ◦C in 20 min  (min).
© Retrieval: the temperature increases to 95 ◦C and becomes stable for
20  min;
© Cool: cooling of the buffer from 95 ◦C to 65 ◦C in 20 min;√
Endogenous peroxidase inhibition: H2O2 at 3% (Bioptica) for 10 min;√
Primary antibody incubation: clone MIB-1 (Bioptica), 1:200 dilution
for 20 min;√
Secondary system: Ultravision Quanto large volume detection kit-HRP
(ThermoScientiﬁc):
©  Enhancer for 10 min;
© Polymer for 10 min;√
Chromogen:  3,3′diaminobenzidine (DAB Quanto) for 5 min
(ThermoScientiﬁc);√
Counterstaining:  Mayer haematoxylin for 3 min;√
Dehydration: arising sequence of alcohol;
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Table 2
Parameters for digital analysis.
Parameter Range Function
Only cells with nucleus ON/OFF Counts only the membrane
associated with a detected
nucleus.
Threshold 0–255 Detachment between
background and nuclei on the
haematoxylin channel.
Minimum area 0–6000 Minimum area under which
the object is identiﬁed as
nucleus.
Crumbling 0–255 Settles the sensibility on the
membrane separation.
Threshold + vs − 0–255 Settles the threshold of
membrane completeness to
classify cells as negative (0) or
positive (1+,2+,3+).
Threshold 2+ vs 3+ 0–255 Settles the average intensity of
complete membrane√
Clariﬁcation with xylene;√
Assembling.
ll immunohistochemical tests were performed using an automatic
tainer (Lab Vision, Thermo Scientiﬁc), following the procedure
hown in Table 1. Each step was followed by washing with Tris-
uffered saline containing Tween 20 (Thermo Scientiﬁc). After July
014, another washing step with running water was added after
ounterstaining, to improve the haematoxylin results. Every slide
ad been evaluated by a pathologist on an optical microscope
ith a low magniﬁcation and classiﬁed as equivocal, in agreement
ith the most recent guidelines of the American Society of Clini-
al Oncology and the College of American Pathologists (ASCO-CAP
013). Cases evaluated before the 2013 guidelines cut-off date,
hich had been classiﬁed using the previous set of guidelines
9], were revaluated, and all were conﬁrmed as equivocal. Each
lide underwent digital acquisition, using a D-Sight Fluo 2.0 dig-
tal microscope (A. Menarini Diagnostics, Firenze, Italy) and was
nalysed with VISIA Imaging s.r.l. software (version 2.5.0.1, San Gio-
anni Valdarno, Italy). The digitizing of a slide requires acquisition
ith a low-magniﬁcation lens (4×)  to create a slide preview, on
hich the area of interest to be scanned with a high-magniﬁcation
ens (20×)  is selected. With this procedure, a digital equivalent of
he slide is obtained, and it can be displayed at any magniﬁca-
ion from 0 to 20×,  maintaining an excellent image quality. The
mportance of using a high-magniﬁcation lens is that the analy-
is software requires a high-resolution image (not less than 20×
agniﬁcation). Every equivocal case underwent a FISH conﬁrming
est (PathVysion Her2 DNA Probe Kit II, Abbot Molecular) evaluated
sing a ﬂuorescent microscope, following international criteria
ASCO-CAP 2013). Results collected before the adoption of these
uidelines were reevaluated, and no changes were seen in the
nal diagnosis for any case. After July 2014, ﬂuorescent slides were
canned with a D-Sight Fluo 2.0 digital microscope, and analysed
ith speciﬁc software.
Digital slides were divided into categories based on:
Type of specimen:  Surgical sample or biopsy.
The difference in the quantity of tumour sample that can be
ound in the two different types of specimen is important, as is the
ubsequent handling of samples during all the steps preceeding the
mmunohistochemical staining to achieve a perfect reaction quality
10].
Suitability for digital analysis: Inadequate or adequate.classiﬁcation as strong (3+) or
moderate (2+).
Some of the slides in our collection did not meet the require-
ments of the analysis software, mostly due to poor quality of the
immunohistochemical signal. These cases were classiﬁed as inad-
equate (technical issues).
• Proﬁle:  A, B, C, D, E, F, G.
The analysis software uses a sequence of parameters that allow
evaluation of staining intensity and of the percentage of the cancer
cell membrane that is stained (Table 2). An accurate analysis of the
slide requires that these parameters be carefully chosen to avoid
misclassiﬁcation of cells. This is directly affected by the quality of
the immunohistochemical reaction, and by the intensity of both the
haematoxylin staining of the nuclei and the 3,3′diaminobenzidine
(DAB) staining and its distribution. Speciﬁc proﬁles have been
developed based on slides with the same staining quality, with ref-
erence to a representative slide, from A to G. Every scanned slide
was evaluated at low magniﬁcation and entered in the appropri-
ate analysis category. A speciﬁc proﬁle (F) was  developed only for
biopsy, even if the staining of the slide is identical to the surgical
specimen that underwent B proﬁle analysis. This is due to the differ-
ent nature of the two  samples, biopsies have fewer tissue quantity
and different histological tissue treatment (ﬁxation and process-
ing) compared to surgical specimens, causing staining differences
that the analysis software can detect, as they are not visible to the
naked eye. It is really important to separate the two proﬁles to avoid
misclassiﬁcation of the slide. Overall, seven different proﬁles were
deﬁned (Table 3), each with its representative slide (Image 1), to
make the analysis reproducible and reliable.
• Staining distribution: Homogeneous, heterogeneous.
DAB staining intensity distribution is an essential parameter in
the choice of the analysis area. Each slide was  visualized at low
magniﬁcation (max 4×) and the staining intensity was  evaluated.
If the distribution was homogeneous, the analysis area was chosen
randomly on the slide. If the distribution was heterogeneous, two
separate areas were chosen, one in the most intense region (hot
spot), another in the weakest, containing approximately an equiv-
alent number of cells. These areas were analysed separately and a
ﬁnal average result from both was considered.When these parameters were set, the image analysis was  per-
formed using a 20×magniﬁcation. It was decided to limit the area
of analysis to 20 mm2 (4× ﬁeld), due to the time-consuming nature
of the analysis (90–120 min). Analysis of the whole section would
T. Marcuzzo et al. / Pathology – Research
Table  3
Proﬁle for the digital analysis.
Proﬁle Parameters Value
A
Grey nuclei, weak
intensity
Representative slide
B13-1404 I
Only cells with nucleus
Threshold
Minimum area
Crumbling
Threshold + vs −
Threshold 2+ vs 3+
OFF
1
10
25
137
77
B
Intense blue nuclei
Representative slide
B14-8580/1B
Only cells with nucleus
Threshold
Minimum area
Crumbling
Threshold + vs −
Threshold 2+ vs 3+
OFF
40
120
25
167
87
C
Faint slide, soft DAB
Representative slide
B12-772 E
Only cells with nucleus
Threshold
Minimum area
Crumbling
Threshold + vs −
Threshold 2+ vs 3+
OFF
1
10
25
172
102
D
Faint slide,
well-deﬁned DAB
Representative slide
B12-9154 G
Only cells with nucleus
Threshold
Minimum area
Crumbling
Threshold + vs −
Threshold 2+ vs 3+
OFF
1
20
10
187
117
E
Grey/blue nuclei,
cytoplasmic or
intense DAB
Representative slide
B12-13575/2C
Only cells with nucleus
Threshold
Minimum area
Crumbling
Threshold + vs −
Threshold 2+ vs 3+
OFF
1
10
25
140
65
F
Biopsy, Intense blue
nuclei
Representative slide
B14-9699
Only cells with nucleus
Threshold
Minimum area
Crumbling
Threshold + vs −
Threshold 2+ vs 3+
OFF
40
10
10
140
60
G
Strong intensity mix
slide (A/E)
Representative slide
Only cells with nucleus
Threshold
Minimum area
Crumbling
OFF
1
10
25
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Threshold + vs −
Threshold 2+ vs 3+
97
35
ave taken an excessive amount of time, and the number of cells in
n area of 20 mm2 was expected to be high enough to be represen-
ative of the whole section. This was demonstrated to be the case
see Results below). The analysis was based on the identiﬁcation
f DAB-positive cell membranes and on the percentage of the cell
embrane stained. Samples were classiﬁed into four categories, as
ollows:
0 Negative: no presence of membrane staining, the analysis ﬁnds
only the haematoxylin staining of the nuclei.
1+ Negative: weak and incomplete staining.
2+ Equivocal: moderate or incomplete membrane staining.
3+ Positive: strong and complete membrane staining.
This classiﬁcation is equivalent to that recommended in the
ost recent published guidelines [1]. Every cell is categorized
ccording to these criteria and the software reports the percent-
ge of cells in each category from the total number of analysed
ells. The ﬁnal result is scored based on a positivity cut-off set at
0% of the total cell number, as negative (0–1+), equivocal (2+),
r positive (3+). Results from each case were compared to those
btained by earlier FISH tests, which are considered the diagnostic
old standard.
Number of cells: Adequate, inadequate. and Practice 212 (2016) 911–918 913
When the total number of analysed cells was less than 10,000,
the whole analysis was  considered unreliable. We  observed that
with fewer cells the positive/negative percentage was strongly
inﬂuenced by the number of cells analysed, with small differences
leading to large changes. Because this variation started to stabilize
above 10,000 cells, we used this number as a reliability thresh-
old. If a single area did not contain enough cells, the analysis was
extended until the minimum threshold was reached. If insufﬁcient
cells were present within the whole section, the slide was  consid-
ered inadequate (<10,000). To test the suitability of the selected
threshold, we examined the total number of cells analysed for all
areas of each slide. All of the analysed areas were included in this
examination, thus one for every homogeneous case (129) and two
for each heterogeneous case (23). Furthermore, we also examined
cell numbers on slides scored as inadequate (<10,000), for a ﬁnal
total of 191 analysed areas.
3. FISH
As previously described, the conﬁrming FISH test needs its anal-
ysis with a ﬂuorescent microscope. The analysis started with an
observation of the slide by the pathologist with a DAPI ﬁlter. This
allowed him to evaluate the nuclei morphology and eventual nuclei
overlapping, choosing the suitable one. Then the DAPI ﬁlter must
be switched with the SpectrumOrange to detect Her2/neu signals
and count them, losing the nuclear morphological detail that the
observer must keep in mind. Then the ﬁlter is switched again to
the SpectrumGreen, to count Cep17 signals. Both the counts were
signed and the observer moved on another nucleus. This process
continued until the achievement of the minimal nuclei number, not
less than 20 nuclei [1]. After July 2014, the evaluation of the FISH
results was made using the digital equivalent of the slide: we used
the D-Sight Fluo 2.0 digital microscope to create digital ﬂuorescent
slide, and then analysed them with the speciﬁc analysis software
made by VISIA. This software is an upgrade of the same used in a
recent article [11] about standardization of completely automated
FISH analysis. The analysis was made on selected areas after exam-
ination of all ﬂuorescent slides. The software scanned the selected
ﬁelds at 60× magniﬁcation. A mercury lamp powered the light
directed on the sample and a DAPI (4,6-diamidino-2-phenylindol)-
stained image was  acquired to identify nuclei, using an automated
perfect focus system. The software proceeded to scan signals from
probes for both Her2/neu (SpectrumOrange) and CEP (Spectrum-
Green), using appropriate ﬁlters, and collecting data from a greater
number of Z-levels compared to the DAPI images. Level number
is adjustable, but for these samples it was  ﬁxed at 13, separated
from each other by 1 m.  The software compressed the scanned
images into one that the user can scroll through, removing back-
ground from both probes. The pathologist gained the advantages of
observing the slide on a screen, and not directly on the ﬂuorescent
microscope, with a high image quality including all ﬁlters and with-
out need of focusing [12]. The software automatically highlighted
the recognizable nuclei and the red and green probes. The pathol-
ogist had to check every nucleus and every signal to control the
suitability of the analysis. If needed, he could erase, modify or add
nuclei or probes signals with a dedicated manual control system.
The software continuously updated its ﬁnal results based on each
probe and nucleus accepted by the pathologist. This allowed a fast,
effective, and reproducible analysis of the selected nuclei. It was
also possible to store high-quality images of each sample, avoiding
loss of sample information due to ﬂuorescence decay. Furthermore,
digital analysis allowed the observation of a greater number of
nuclei compared to direct optical ﬂuorescent microscopy evalua-
tion. The most recent guidelines [1] changed the minimum number
of nuclei that a pathologist must count to give a reliable result,
decreasing it from 60 to 20. In this study, we tested for effects of
914 T. Marcuzzo et al. / Pathology – Research and Practice 212 (2016) 911–918
resen
t
m
n
s
n
d
e
b
t
4
4
1Image 1. Rep
his reduction. Each of the 49 Her2 FISH digitised cases was  counted
ultiple times, starting from a minimum of 20 and increasing the
umber evaluated until the maximum analysable nuclei within the
elected areas was achieved (20, 30, 40, 50, 60, max). The highest
umber of analysable nuclei ranged from 65 to 384. Results using
ifferent cell counts were compared, to determine if it had inﬂu-
nced the ﬁnal scoring. In these cases, the ﬁnal result was obtained
y agreement of two pathologists, experts in ﬂuorescence interpre-
ation.
. Results.1. Cell number distribution
Cell numbers within the analysed areas ranged from 987 to
27,933, with a mean of 35,483.26; the standard deviation wastative slides.
25,844.91. Furthermore, 50% of the samples contained between
16,793 and 46,304 cells.
4.2. General results (Table 4)
Of the 176 total cases, 24 were inadequate (12 for technical
issues and 12 for cell numbers <10,000), 85 (48.3%) were conﬁrmed
as equivocal, 23 and 44 were classiﬁed as negative (13.1%) and
positive (25.0%), respectively .
In comparison to the gold standard method of FISH the 85
equivocal cases conﬁrmed as equivocal, 67 cases were correctly
reclassiﬁed as positive or negative, whilst 5 cases were discordant
compared to FISH. These cases were classiﬁed as ampliﬁed by dig-
ital analysis and not ampliﬁed by FISH. Of all our clinical records
(176) the digital analysis of 62 cases is concordant with the FISH
results (35%). However, results from ﬁve cases (3%) did not agree
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Table  4
Characteristics of slides classiﬁcation after HER 2 immunohistochemistry digital
analysis (176 cases).
Characteristic N %
Diagnostic Categories
Inadequate 24 14%
Negative (1+/0) 23 13%
Positive (3+) 44 25%
Equivocal (2+) 85 48%
Total 176 100%
Type  of Specimen
Surgical Sample 132 75%
Core  Biopsy 44 25%
Total 176 100%
Suitability for IHC digital analysis
Inadequate 24 14%
Adequate 152 86%
Total 176 100%
Staining Distributiona
Homogeneous 139 85%
Heterogeneous 25 15%
Total 164 100%
Concordance Rate between IHC
Digital Analysis and FISH testb
FISH concordant 62 41%
FISH discordant 5 3%
Equivocal (2+) 85 56%
Total 152 100%
a Excluded 12 cases for the impossibility to evaluate the distribution.
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Table 5
Comparison between FISH Analysis and Digital Analysis (excluded 85 equivocal and
24  inadequate cases).
Digital IHC  Analyis
Positive (3+) Negative (1+) Total
FISH Analyis Ampliﬁed 39 0 39
Not Ampliﬁed 5 23 28
Total 44 23 67
T
Db Excluded 24 inadequate cases.
ith FISH ﬁndings These ﬁve cases will be described in detail in the
iscussion.
The 24 samples (14% of cases) that were inadequate for digital
nalysis were excluded from some of the following investigations,
ecreasing the clinical records to 152.
.3. Sensitivity and speciﬁcity of the digital method (Table 5)
In the comparison between FISH analysis and digital analysis
e excluded the 85 equivocal (2+) cases and also the 24 inade-
uate ones. Therefore the analysis is focused on 67 cases, of which
9 showed ampliﬁcation by FISH, while 28 were not ampliﬁed.
ith the digital IHC evaluation, in most cases there was concor-
ance with the FISH evaluation (62 cases of 67), except for ﬁve
ases (false positives) for which the instrument identiﬁed hyper-
xpression where it was not ampliﬁed (positive predictive value of
he digital method VPP = 89% [95% CI 78–95%]). The sensitivity and
peciﬁcity of the digital method were 100% (95% CI [93–100%]) and
2% (95% CI [71–90%]), respectively .
able 6
igital Analysis according to Type of Specimens.
Characteristic Surgical Sam
Diagnostic Categories
Inadequate 16 (12%) 
Negative (1+/0) 16 (12%) 
Positive (3 + ) 32 (24%) 
Equivocal (2 + ) 68 (52%) 
Total  132 
Concordance Rate between Digital Analysis and FISH testa Surgical Sam
FISH  concordant 44 (38%) 
FISH  discordant 4 (3%) 
Equivocal (2 + ) 68 (59%) 
Total  116 
a Excluded inadequate cases.4.4. Comparison between types of specimen (Table 6)
The records included 132 (75%) surgical specimens and 44 (25%)
biopsies. The were no statistical differences between the propor-
tions of inadequate samples in biopsies and in surgical specimens
(18% vs 12%, p = 0.47). However, there were a number of samples
that remained equivocal after digital analysis, and more of them
were found among surgical specimens than in biopsies. Evaluat-
ing the concordance percentage with FISH analysis we found it
to be slightly higher among biopsy samples but not statistically
signiﬁcant (50% vs 38%, p = 0.27) .
4.5. Comparison between staining distributions (Table 7)
Among the analysis of 164 samples (12 were excluded for
the impossibility to evaluate the distribution), 139 (85%) showed
homogeneous staining. Furthermore, in both homogeneous and
heterogeneous staining categories, there was a high number of
equivocal cases. Focusing on the non-equivocal cases, in homoge-
neous samples, the percentage of FISH-discordant cases was  2% (1
case in 58), while in heterogeneous cases, which were fewer in
number, the discordant case percentage was 17% (p = 0.005). The
single homogenous discordant case was  a biopsy, while all four
heterogeneous discordant cases were surgical specimens .
4.6. Comparison among three years (Table 8)
We divided the ﬁnal results into the three years of the study, and
examined them separately. The number of cases classiﬁed as equiv-
ocal decreased over time, from 50% of total cases in 2012 to 42%
in 2014. The percentage of cases with non-equivocal ﬁnal results,
concordant with FISH, increased from 22% in 2012 to 44% in 2014.
However, a small percentage of discordant cases was  present dur-
ing all years. The fraction of cases scored as inadequate for technical
reasons decreased from 12% to 5% during the three years examined
(Image 2) .
ple Core Biopsy p-value p-trend
0,43
8 (18%) 0,47
7 (16%) 0,69
12 (27%) 0,84
17 (39%) 0,19
44
ple Core Biopsy p-value p-trend
18 (50%) 0,27 0,44
1 (3%) 1
17 (47%) 0,31
36
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Table 7
Digital Analysis according to Staining Distributions.
Characteristic Homogeneous Heterogeneous p-value p-trend
Diagnostic Categories p = 0.83
Inadequate 10 (8%) 2 (8%) 1
Negative (1+/0) 21 (16%) 2 (8%) 0,45
Positive (3+) 37 (29%) 7 (28%) 1
Equivocal (2+) 71 (55%) 14 (56%) 1
Total  139 25
Concordance Rate between Digital Analysis and FISH test* Homogeneous Heterogeneous p-value p-trend
FISH  concordant 57 (44%) 5 (22%) 0,07 <0.001
FISH  discordant 1 (1%) 4 (17%) 0.005
Equivocal (2+) 71 (55%) 14 (61%) 0,77
Total  129 
* Inadequate cases were excluded.
Table 8
Result comparison: 2012–2014.
D-sight results 2012 2013 2014
Inadequate cell N◦ < 10.000 6 12% 2 3% 4 6%
Inadequate for technical pitfall 6 12% 3 5% 3 5%
Equivocal 26 50% 33 52% 26 42%
FISH  concordant 11 22% 24 38% 27 44%
FISH  discordant 2 4% 1 2% 2 3%
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5.3. Sensitivity and speciﬁcity of the digital methodTotal amount 51 100.0% 63 100.0% 62 100.0%
.7. FISH
Of the 49 cases analysed by FISH with the digital procedure, 41
howed no variation in results based on the different numbers of
otal nuclei counted. The remaining eight cases did show differ-
nces between results obtained from counting the ﬁrst 20 nuclei
nd from one other total count category. Moreover, we observed
hat only the 40-nuclei counts gave the correct result in all cases.
. Discussion
We  compared the results of traditional Her2 IHC evaluation with
 speciﬁc software package (VISIA Imaging) for Her2 IHC analysis,
sing FISH as gold standard. To clearly investigate if the application
f digital IHC analysis software could lead to a decrease of FISH test
nd more rapid, reproducible and reliable IHC results, we discuss
ach step separately.
Image 2. Inadequate and Disco23
5.1. Cell number distribution
A minimum of 10,000 cells appeared to be an ideal cut-off for
reliability of this analytic data, conﬁrming earlier anecdotal evi-
dence. Indeed, more that 75% of cases in this study provided higher
cell numbers, and 50% of samples contained between 16,000 and
46,000 cells. Therefore, we  consider the analysis we  have conducted
to be reliable. Result from cases with fewer cell number should not
be considered.
5.2. General results
Some samples may  not be suitable for digital analysis, due to
characteristics of the sample, as in the case of low cell number
previously described, or to technical limitations. It is important to
separate these two reasons, as the ﬁrst is an independent variable
(because we cannot determine the number of cancer cells present
in a sample) while the other is determined by the quality of the
immunohistochemical assay. We have demonstrated that results
in 35% of all equivocal cases, with evaluation by optical microscopy,
could be better deﬁned by digital analysis avoiding FISH. In a routine
use perspective this system will decrease by a third the ﬂuores-
cence conﬁrming test. The diagnostic contribution that the digital
method brings on this matter is undoubtedly relevant.Digital test appeared to have 100% sensitivity, due to the absence
of false negatives. However, the presence of FISH-discordant cases
rdant trend during time.
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annot be ignored. In the whole set of samples there were ﬁve false-
ositives which decreased the test speciﬁcity to 82%.
.4. Comparison between types of specimen
The inadequate percentage is similar in both categories, even if
t was slightly higher in biopsies. Considering the ﬁve FISH discor-
ant cases in detail, four of them were surgical specimens, while
ne was a biopsy. Biopsies represent a smaller number of samples
ompared to surgical specimens, but have a slightly higher frac-
ion of inadequate samples. This is inherent to the samples, which
resent complex challenges to both pre-analytic standardization
nd immunohistochemical methods. Furthermore, most biopsies
amples contain evident artefacts of over- or under-staining due
o sample handling, often focused on borders or seen in small-
imension samples. The difference between biopsies and surgical
amples immunohistochemistry could be of great inﬂuence for
ome markers and there is variance even for Her2 [13]. This dif-
erence has been reported also in other studies on other tissue
amples [14]. Guidelines recommend a large group of situations in
hich IHC test on a single biopsy sample is not adequate and new
er2 test on the surgical specimen must be done [1]. The certainty
f correct tissue handling and of IHC method decreases the risks
f altered staining and improves digital analysis. A recent study
nderlined the fact that a percentage of samples scored as posi-
ive (3+) by the pathologist, using optical microscopy, were found
ot to be ampliﬁed after FISH test [15]. This shows that there are
ew samples with high membrane staining that do not have gene
mpliﬁcation. All these factor lead to discrepancies when a biopsy
s analysed, even with automated digital software.
.5. Comparison between staining distribution
Heterogeneous cases present different staining intensities
ithin the same sample.
Frequently it is unclear if variation in intensity is due to focal
yperexpression or is related to artefacts (id: delays in ﬁxation,
verﬁxation, automatic stainer malfunction, or to other reasons
elated to preanalytical and analytical phases [10,16]). In all het-
rogeneous cases we selected two areas with differential staining
ontaining comparable cell numbers. Considering the ﬁve FISH dis-
ordant cases, four of them are surgical specimens that present a
eterogeneous staining distribution. Heterogeneous cases should
e interpreted with caution.
.6. Comparison among the years
During the three years of this study, the quality of the immuno-
istochemical assay changed, due to a strict standardisation of
re-analysis processes and increased control of the immunohisto-
hemical methods. Cold ischemia and formalin ﬁxation time were
arefully standardized as suggested by international guidelines
1,9], antibody speciﬁcity was periodically tested on positive and
egative control tissue, and the analytic activity was  submitted
o external quality control (NordiQC). Particularly useful was  the
tandardization of haematoxylin counterstaining. A good-quality
ample is essential to perform a reliable digital analysis. Lower
ample quality risks inaccurate digital results.
.7. FISH
We  observed that limiting the total evaluated nuclei to 20 could
ead to doubtful classiﬁcations, but also to extend the count to an
xcessively high nuclei number did not improve the reliability of
esults. We  suggest that 40 is the ideal nuclei number for a reliable
ount.
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6. Conclusion
This analysis software of immunohistochemistry Her2 slide has
signiﬁcant value and utility in the prognostic-predictive evaluation
of breast cancer. It gives results needed to patient therapy very
rapidly, avoiding the use of FISH on a third of total cases. Digital
analysis is also simple to apply, highly sensitive, and reproducible
when properly arranged. However, the risks of misclassiﬁcation,
although low, are not entirely removable, and we believe that
heterogeneous-staining cases should be conﬁrmed by FISH testing.
While the ideal sample for digital analysis is a surgical specimen,
if the only available sample is a biopsy, it will be important to be
certain of its correct processing and staining. If doubts on its han-
dling are present, FISH may  also be required. In the analysis of FISH,
a reliably correct evaluation may  require increasing the number of
nuclei examined to 40. The application of this analysis software can
lead to an improved interpretation of equivocal cases, decreasing
the need for FISH evaluation, and increasing diagnostic certainty
and reproducibility.
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